- AstraZeneca is expected to announce a drug pricing agreement with U.S. President Donald Trump.
- The pact is part of a broader effort by the Trump administration to lower drug prices in the United States.
- Details of the agreement have not been made public.
- This follows a similar deal with Pfizer that included discounted medications and major domestic investments.
- Shares of AstraZeneca fell nearly 1% after news broke, but have risen over 29% so far this year.
AstraZeneca is expected to finalize an agreement with U.S. President Donald Trump to reduce drug prices, according to a report from Bloomberg News. The deal would represent the second pharmaceutical partnership aimed at advancing one of the Trump administration’s core healthcare initiatives.
The specific terms of the pact were not disclosed, but the agreement is part of ongoing efforts by the U.S. government to make prescription medications more affordable. The administration also seeks to ensure wealthier nations make a greater contribution to funding medical innovation.
A similar arrangement was reached with Pfizer in September. That deal included significant price reductions on commonly prescribed medications and a $70 billion investment in U.S. manufacturing infrastructure. President Trump stated that “Pfizer agreed to supply several of its most commonly used medications at heavily discounted prices of anywhere between 50% and even 100%.”
Market response to the news was modest, with AstraZeneca shares dropping nearly 1% in afternoon trading. Despite the dip, the company’s stock price remains substantially higher for the year, gaining more than 29% so far and nearly 10% over the past 12 months.
A public announcement regarding the pact with AstraZeneca could take place at the White House as early as Friday, according to sources mentioned in the report. The move strengthens the administration’s push for lower drug costs and may encourage other companies to participate in similar initiatives.
Previous Articles:
- Bitcoin Core v30 Release Raises ETF Power Concerns Amid Fork Fears
- Hedera HBAR Slides as Institutional Selloff Drives Volatility
- Storm-2657 Targets US Universities, Diverts Payroll via SaaS Hacks
- Major Global Banks Unite to Launch Joint Stablecoin Initiative
- EU Prepares New Trade Deal Plan, Rejects Trump Regulatory Demands
